Texas Permanent School Fund trimmed its holdings in Exponent, Inc. (NASDAQ:EXPO) by 7.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,447 shares of the business services provider’s stock after selling 1,383 shares during the quarter. Texas Permanent School Fund owned about 0.07% of Exponent worth $1,240,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Advisor Group Inc. lifted its stake in Exponent by 15.4% in the second quarter. Advisor Group Inc. now owns 2,131 shares of the business services provider’s stock valued at $124,000 after buying an additional 284 shares during the last quarter. Trexquant Investment LP purchased a new stake in Exponent in the third quarter valued at approximately $224,000. Cubist Systematic Strategies LLC purchased a new stake in Exponent in the third quarter valued at approximately $242,000. Stifel Financial Corp purchased a new stake in shares of Exponent during the third quarter worth approximately $249,000. Finally, Amalgamated Bank raised its stake in shares of Exponent by 5.1% during the second quarter. Amalgamated Bank now owns 3,553 shares of the business services provider’s stock worth $207,000 after purchasing an additional 171 shares during the last quarter. 88.97% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently commented on EXPO shares. Zacks Investment Research upgraded Exponent from a “hold” rating to a “buy” rating and set a $82.00 price target for the company in a research note on Tuesday, January 23rd. BidaskClub upgraded Exponent from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Cantor Fitzgerald upped their price target on Exponent to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, October 19th. Finally, SunTrust Banks upgraded Exponent from a “hold” rating to a “buy” rating and set a $84.00 price target for the company in a research note on Friday, January 26th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $82.67.
Exponent, Inc. (NASDAQ EXPO) opened at $72.10 on Tuesday. The stock has a market capitalization of $1,860.95, a price-to-earnings ratio of 37.75 and a beta of 0.72. Exponent, Inc. has a 52-week low of $56.43 and a 52-week high of $78.39.
Exponent (NASDAQ:EXPO) last released its quarterly earnings data on Thursday, February 1st. The business services provider reported $0.47 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.05. The firm had revenue of $82.72 million during the quarter, compared to analysts’ expectations of $80.27 million. Exponent had a return on equity of 17.81% and a net margin of 11.88%. Exponent’s revenue was up 13.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.39 earnings per share. analysts expect that Exponent, Inc. will post 2.41 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 23rd. Shareholders of record on Friday, March 2nd will be given a $0.26 dividend. This is a boost from Exponent’s previous quarterly dividend of $0.21. The ex-dividend date is Thursday, March 1st. This represents a $1.04 annualized dividend and a yield of 1.44%. Exponent’s dividend payout ratio is presently 55.26%.
Exponent Company Profile
Exponent, Inc (Exponent), along with its subsidiaries, is a science and engineering consulting company. Exponent provides engineering and scientific consulting services to clients around the world. Its service offerings are provided on a project-by-project basis. It operates in two segments: Engineering and Other Scientific, and Environmental and Health.
Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.